ATE396403T1 - Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen - Google Patents

Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen

Info

Publication number
ATE396403T1
ATE396403T1 AT99912898T AT99912898T ATE396403T1 AT E396403 T1 ATE396403 T1 AT E396403T1 AT 99912898 T AT99912898 T AT 99912898T AT 99912898 T AT99912898 T AT 99912898T AT E396403 T1 ATE396403 T1 AT E396403T1
Authority
AT
Austria
Prior art keywords
plasminogen activator
urocinasis
micrometastasis
diagnosis
target
Prior art date
Application number
AT99912898T
Other languages
English (en)
Inventor
Shafaat A Rabbani
Richard Hart
Original Assignee
Univ Mcgill
American Diagnostica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill, American Diagnostica Inc filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE396403T1 publication Critical patent/ATE396403T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99912898T 1998-03-23 1999-03-23 Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen ATE396403T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/046,106 US6077508A (en) 1998-03-23 1998-03-23 Urokinase plasminogen activator receptor as a target for diagnosis of metastases

Publications (1)

Publication Number Publication Date
ATE396403T1 true ATE396403T1 (de) 2008-06-15

Family

ID=21941655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912898T ATE396403T1 (de) 1998-03-23 1999-03-23 Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen

Country Status (9)

Country Link
US (2) US6077508A (de)
EP (1) EP1064005B1 (de)
JP (1) JP2002507574A (de)
AT (1) ATE396403T1 (de)
AU (1) AU3116099A (de)
CA (1) CA2323743C (de)
DE (1) DE69938778D1 (de)
ES (1) ES2307333T3 (de)
WO (1) WO1999048509A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US6896870B1 (en) 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
JP2003528035A (ja) * 1999-10-01 2003-09-24 アングストロム ファーマシューティカルズ， インコーポレイテッド ｕＰＡおよびｕＰＡＲを標的化する診断プロ−ブおよび治療薬
DE60219888T2 (de) * 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
EP1393743A1 (de) * 2001-01-25 2004-03-03 Fondazione Centro San Raffaele Del Monte Tabor Substanzen zur Modulierung der uPA/uPAR Aktivität zur Behandlung von AIDS
BRPI0210903B8 (pt) * 2001-05-18 2021-07-27 Virogates Aps método de diagnóstico ou prognóstico de principais patógenos bacterianos respiratórios em um indivíduo
AU2002364945A1 (en) * 2001-10-25 2003-07-09 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
WO2004100759A2 (en) * 2003-05-19 2004-11-25 Quark Biotech, Inc. Endo 180 receptor for diagnosis and treatment
US20070190068A1 (en) * 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
WO2007134274A2 (en) * 2006-05-12 2007-11-22 Attenuon, Llc Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
EP2411413B1 (de) 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Verbindungszusammensetzungen und verfahren zur behandlung von krebs und fibrotischen krankheiten
CN112630442A (zh) * 2020-11-03 2021-04-09 浙江大学 一种血浆可溶性尿激酶型纤溶酶原激活物受体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US5015571A (en) * 1983-08-17 1991-05-14 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
CA2094276C (en) * 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
EP0642354A4 (de) * 1991-11-18 1995-07-12 Univ Michigan VERFAHREN ZUM NACHWEISS UND ISOLATION uPA-R UND INHIBIERUNG DER BINDUNG uPA MIT uPA-R.
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
US5429133A (en) * 1992-12-18 1995-07-04 Neoprobe Corporation Radiation responsive laparoscopic instrument
US5441050A (en) * 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DE69432608T2 (de) * 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
GB9626708D0 (en) * 1996-12-23 1997-02-12 Domino Printing Sciences Plc Continuous ink jet print head control
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases

Also Published As

Publication number Publication date
CA2323743A1 (en) 1999-09-30
EP1064005A1 (de) 2001-01-03
ES2307333T3 (es) 2008-11-16
JP2002507574A (ja) 2002-03-12
DE69938778D1 (de) 2008-07-03
CA2323743C (en) 2010-08-31
US6077508A (en) 2000-06-20
AU3116099A (en) 1999-10-18
WO1999048509A1 (en) 1999-09-30
US20040265229A1 (en) 2004-12-30
EP1064005B1 (de) 2008-05-21
EP1064005A4 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
ATE396403T1 (de) Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
DK1084145T3 (da) Antistoffer imod ED-B-domænet i fibronectin, konjugater indeholdende disse og anvendelse deraf til diagnosticering og behandling af tumorer og sygdomme forbundet med angiogenese
CY1109062T1 (el) Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως
DE60326567D1 (de) Diagnose von hepatozellulärem karzinom
DE60117592T8 (de) Diagnose von pre-eclampsia
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
TR200001333T2 (tr) Kiral amin oksazolinil ligandlara dayanan geçiş metali katalizlenmiş tepkimeler
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE317126T1 (de) Liganden für den nachweis von prionen
DE60133558D1 (de) Direkte bestimmung des quotients von analyt- zu referenzmolekülen
FR2771751B1 (fr) Erythrovirus et ses applications
DE69839314D1 (de) Diagnosemittel für Diabetes, das 13C-markierte Zusammensetzung enthält
EP2002021A4 (de) Verfahren zur untersuchung von protein-protein-interaktionen
EP1572225A4 (de) Thrombospondinfragmente und deren verwendung bei klinischen krebs-tests und der erzeugung von antikörpern und sonstigen bindungsmitteln
WO2003104424A3 (en) Novel molecular conjugates for signal amplification
Goscinski et al. Seprase, Dipeptidyl Peptidase IV and Urokinase-Type Plasminogen Activator Expression in Dysplasia and Invasive Squamous Cell Carcinoma of the EsophagusA Study of 229 Cases from Anyang Tumor Hospital, Henan Province, China
DE69508605D1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
DE69941292D1 (de) Schlange, pseudonaja textilis textilis
WILL et al. Expression of urokinase-type plasminogen-activator (uPA) and Its receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion capacity
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties